Navigation Links
Experts from Stevens, Merck, publish joint paper, 'Biosynthetic Studies of Platensimycin'
Date:12/6/2007

HOBOKEN, N.J. Stevens Institute of Technologys Professor Athule B. Attygalle and his doctoral student Kithsiri B. Herath have collaborated with Merck Pharmaceuticals Dr. Sheo B. Singh on a study whose findings have been published in the Journal of the American Chemical Society, in a paper titled Biosynthetic Studies of Platensimycin (Herath, K. B.; Attygalle, A. B.; Singh, S. B. J. Am. Chem. Soc.; [Communication]; 2007; ASAP Article; DOI: 10.1021/ja0758943from academia and industry).

It reports biosynthesis of a novel antibiotic, said Attygalle. It is the product of a rewarding research effort done with Merck, with Dr. Singhs participation.

Platensimycin (1) and platencin (2), two novel antibiotics, were recently isolated from several strains of Streptomyces platensis.

They impart their potent Gram-positive antibacterial activity, including that against drug-resistant organisms (e.g., MRSA, VRE), by uniquely inhibiting acyl enzyme intermediates of the condensing enzymes FabF and FabF/FabH, respectively, vital for fatty acid biosynthesis.

Both compounds are highly efficacious in vivo when administered by continuous infusion; however, the efficacy is reduced when administered by conventional routes. This phenomenon is attributed to their poor pharmacokinetic properties which could potentially be improved by chemical modification of the natural product, via total synthesis and through combinatorial biosynthesis.

Understanding biosynthetic pathways leading to the biosynthesis of both compounds is a prerequisite for combinatorial biosynthesis and is also helpful for improvement of the titer of these compounds in the producing organism. The report details the resultsof biosynthetic studies of platensimycin by stable-isotope precursor incorporation experiments.


'/>"/>

Contact: Patrick A. Berzinski
pberzins@stevens.edu
201-216-5687
Stevens Institute of Technology
Source:Eurekalert

Page: 1

Related biology news :

1. Leading experts cite poor health and nutrition as major barrier to education in developing world
2. Improving science, technology in Africa is aim as G-8, African, UN experts convene in Berlin
3. Less Arctic ice means higher risks, experts warn
4. Soil, conservation experts to reflect on Hurricane Katrina disaster
5. Now is Africas turn for a green revolution, global experts say
6. Agriculture experts meet in Beijing to examine impacts of food prices and climate change on farmers
7. First individual genome sequence published
8. Springer increases publishing activities in South Korea
9. Springer will publish Journal of Coastal Conservation
10. Institution of Chemical Engineers chooses Elsevier as publishing partner
11. New tarpon, bonefish compendium published
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
(Date:2/28/2017)... 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical ... of autoimmune diseases, asthma and allergic diseases and ... quarter and full year ended December 31, 2016 ... business and clinical highlights. "During 2016, ... pipeline by starting five clinical trials across our ...
(Date:2/28/2017)... ... February 28, 2017 , ... The ... well as to their processing and transport properties. With the Litesizerâ„¢ 100 ... of samples. The Litesizerâ„¢ 100 gives rapid and accurate insight into particle systems, ...
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... ... trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel and ... 15 years of meeting this unique need within the biotechnology and pharmaceutical industries ...
Breaking Biology Technology: